|
市場調查報告書
感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會
Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma
|
感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會 是由出版商Decision Resources, Inc.在2011年06月所出版的。
這份英文市場調查報告書價格從美金9200起跳。
感染疾病疫苗，為了確立安全性和製造商的保證，儘管臨床成功，仍然存在的未滿足需求促進新的疫苗開發。
本報告提供全球感染病疫苗市場的規模與到2017年為止的預測，未滿足需求和疫苗開發趨勢，產業的合併，收購，合作趨勢等彙整資料，為您概述為以下內容。
摘要整理
簡介
疫苗市場
主要的發展與新機會
- HIV疫苗開發
- 人類乳突病毒(HPV)疫苗:子宮頸癌等
- 人類乳突病毒(HPV)疫苗與子宮頸癌
- 人類乳突病毒(HPV)疫苗與其他癌症
- 新興市場上人類乳突病毒(HPV)疫苗
- 人類乳突病毒(HPV)疫苗和成人的疫苗接種，擴大性傳染病的疫苗接種的潛在能力
- 疫苗的安全性
- 新興市場
- 理想的人口趨勢
- 醫療制度的發展
- 官民的醫療資金擴大
- 疫苗接種率趨勢
- 新興市場上跨國公司的疫苗策略
調查結果
疫苗產品相關的臨床的未滿足需求
- 新疫苗產品
- 疫苗取得的擴大與資金
- 推薦的免疫疾病計劃的患者適合性提高
- 高風險患者的識別
大型製藥公司的疫苗風險企業:主要交易
- Pfizer/Wyeth
- Johnson & Johnson/Crucell
- Intercell/?
- Sanofi/VaxDesign
- Emergent BioSolutions/Various Partners
- Merck/Hawaii Biotech
- Liquidia Technologies/Bill and Melinda Gates Foundation
今後預測
- 疫苗推動市場的要素
- 確立的疾病領域的擴大
- 已開發國家的價格環境改善
- 對應可能的人口擴大
- 疫苗安全相關的緩慢的現象
- 疫苗阻礙市場的要素
- 新制疫苗上市很少
- 與抗生素及抗病毒藥物的競爭
- 新興市場上潛在的障礙
圖表
Abstract
Introduction:
"By sheer numbers, it' s a huge pool of people that immunizations could really
reach and make an enormous impact." So one surveyed physician describes the
potential impact of vaccines for infectious disease. Indeed, the size of the
population is one reason why companies are taking a fresh look at the vaccine
sector. An increasing global reach, clinical accomplishments, strides in
establishing vaccine safety and manufacturer security, and ongoing unmet needs
are also fueling vaccine development.
Questions Answered in This Report:
- The vaccine marketplace is highly concentrated. What is the size of
this market, and what is its growth trend? Which companies are the leaders
based on 2010 sales? Will those rankings change? What opportunities are
available to these and other contenders in the vaccines space?
- Pfizer bought its way into the upper echelons of the vaccine marketplace
by acquiring Wyeth in 2009. Why would a company like Pfizer be attracted to
a potential acquiree' s vaccine assets? What other notable recent deals have
occurred in the vaccines arena?
- Shortly after HIV was identified as the cause of AIDS in the early 1980s,
Health and Human Services Secretary Margaret Heckler famously declared that a
vaccine would be available within two years. What is the status of HIV
vaccine development? What challenges must researchers confront? What are the
considerations related to prophylactic versus therapeutic vaccines for HIV?
- In December 2010, the FDA approved Merck' s Gardasil for the prevention of
anal cancers. What is next for Gardasil and GlaxoSmithKline' s Cervarix?
What impact will their availability have on approaches to immunization for
adolescents?
- Studies have shown that vaccines are not the cause of autism. How is
this finding influencing perceptions of vaccine safety, according to surveyed
clinicians? What other steps are being taken to ensure vaccine safety - and
vaccine manufacturer security?
- Emerging markets are drawing the attention of pharmaceutical companies,
including vaccine manufacturers. What are the pros and cons of selling
vaccines in emerging markets? Which companies have established a notable
presence in emerging markets?
Scope:
Primary research: Results from a Web-based survey of 106 U.S.
physicians who administer infectious disease vaccines: infectious disease
specialists, pediatricians, and primary care physicians (PCPs).
Market size: Worldwide and U.S. market size over 2005-2017; key
competitors and their market share; market drivers and constraints.
Unmet needs: By segment, age-group, pathogen, and need in the clinical
setting.
Salient events and trends: HIV vaccine development, prime-boost
approach, RV-144, broadly active neutralizing antibodies (bnAbs), therapeutic
versus prophylactic HIV vaccines, HPV vaccinations, adolescent immunization
schedules, vaccine safety, vaccine/autism link, vaccine needs and challenges
in emerging markets.
Deals: Select mergers, acquisitions, and partnerships and how they
demonstrate opportunity and strategy.
Displays: 27 data-rich tables and figures.
Table of Contents
Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Vaccine Market
Key Developments and New Opportunities
- HIV Vaccine Development
- HPV Vaccines - Cervical Cancer and Beyond
- HPV Vaccines and Cervical Cancer
- HPV Vaccines and Other Cancers.
- HPV Vaccines in Emerging Markets
- HPV Vaccines and the Potential to Extend Adolescent Vaccination and
Vaccination Against STDS
- Vaccine Safety
- Emerging Markets
- Favorable Population Dynamics
- Healthcare System Development.
- Expansion of Public and Private Healthcare Funding
- Immunization Rate Momentum
- Multinationals' Vaccine Strategies in Emerging Markets.
Survey Findings
- Guidelines.
- Current Practice.
- Issues Concerning Pediatric Vaccines.
- Access 33
Clinical Unmet Needs for Vaccine Products
- Novel Vaccine Products.
- Greater Access to and Funding for Vaccines
- Improving Patient Compliance with Recommended Immunization Schedules
- Identification of High-Risk Patients
Big Pharma' s Vaccine Ventures - Key Deals.
- Pfizer/Wyeth
- Johnson & Johnson/Crucell
- Intercell/?
- Sanofi/VaxDesign
- Emergent BioSolutions/Various Partners
- Merck/Hawaii Biotech
- Liquidia Technologies/Bill and Melinda Gates Foundation
Outlook.
- Vaccine Market Drivers
- Growth in Established Disease Areas
- Improving Price Environment in Developed Markets
- Expanding Addressable Populations
- Slowly Declining Fears over Vaccine Safety
- Vaccine Market Constraints
- Fewer Novel Vaccine Launches
- Competition from Antibiotics and Antivirals.
- Potential Obstacles in Emerging Markets
Tables
- 1. Challenges in Developing a Vaccine Against HIV
- 2. U.S. Vaccination Guidelines
Figures
- 1. Worldwide Sales of Vaccines, 2005-2010.
- 2. Vaccines: Top Companies Based on Worldwide Sales, 2010
- 3. Worldwide Market Share: Vaccines by Indication, 2010
- 4. Human Immunodeficiency Virus Structure
- 5. Effect of HPV Vaccination on Number of Newly Diagnosed Incident Cases
of Cervical Cancer in the United States, Europe, and Japan, 2010-2040
- 6. Incidence of HPV-Related Cancers and Proportion of HPV 16/18 Cancers in
Men and Women in the Netherlands, 1999-2003
- 7. Survey Question: For your patients who take Gardasil, what are the top
two reasons for patient noncompliance in completing all doses of Gardasil?
- 8. Immunization Rates in Developing Countries
- 9. Survey Question: In what region is your practice(s) located?
- 10. Survey Question: Do you feel that pediatric and adult immunization
guidelines are kept sufficiently up-to-date?
- 11. Survey Question: Do you feel that pediatric and adult immunization
guidelines are sufficiently comprehensive?
- 12. Survey Question: Do you feel that pediatric and adult immunization
guidelines are well communicated to physicians?
- 13. Survey Question: What percentage of your patients receives the
following vaccines each year?
- 14. Survey Question: What percentage of your patients receives the
following vaccines each year (by specialty)?
- 15. Survey Question: In the past (3+ years ago), did you find that parents
of pediatric patients declined or hesitated to vaccinate children because of
fears of adverse outcomes such as autism?
- 16. Survey Question: What is your opinion regarding administration of
three to four pediatric vaccines simultaneously?
- 17. Survey Questions: What percentage of patients in general do you
believe miss out on recommended vaccinations based on lack of access to care?
- 18. Survey Question: What factors might prevent an insurance company from
paying for a vaccine?.
- 19. Survey Question: Which subgroup of patients do you believe has the
greatest unmet needs?
- 20. Survey Question: Which do you believe the greatest unmet need to be?
- 21. Survey Question: What are the top three pathogens for which emerging
vaccines would deliver the greatest overall benefit (six highest-ranking
pathogens)?
- 22. Estimated Worldwide Sales of Vaccines, 2011-2017
- 23. Vaccines: Top Companies Based on Projected Worldwide Sales, 2017.
- 24. Survey Question: Where do you think near-term (next five years)
investment in vaccines will come?
- 25. Worldwide Market Share: Current and Emerging Vaccines, 2017
|
